Status:
COMPLETED
Effects of the Anti-inflammatory Flavonoid Luteolin on Behavior in Children With Autism Spectrum Disorders
Lead Sponsor:
Attikon Hospital
Conditions:
Autism Spectrum Disorders
Eligibility:
All Genders
4-10 years
Phase:
PHASE2
Brief Summary
Background. Increasing evidence indicates that brain inflammation is important in the pathogenesis of neuropsychiatric disorders, including at least a significant proportion of subjects with Autism sp...
Eligibility Criteria
Inclusion
- ASD clinical diagnosis
- Meeting the cutoff score on the DSM-IV-TR symptom list
- Meeting the cutoff score on the Autism Diagnostic Observation Schedule algorithm, at least for ASD
Exclusion
- any medical condition likely to be etiological for ASD \[eg, Fragile X syndrome, tuberous sclerosis\],
- any neurologic disorder involving pathology above the brain stem \[other than uncomplicated nonfocal epilepsy\],
- any evidence of probable neonatal brain damage,
- mastocytosis \[including urticaria pigmentosa\]
- a history of systemic inflammatory diseases
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01847521
Start Date
December 1 2011
End Date
March 1 2013
Last Update
May 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikon Hospital
Chaïdári, Athens, Greece, 124 62